Is bimzelx better than taltz for skin clearing?

Why are patients choosing Bimzelx over Taltz?

Research suggests that Bimzelx, an IL-17A inhibitor, is competing with Taltz (ixekizumab) in the treatment of moderate to severe plaque psoriasis [(1)]. Both medications target the underlying causes of psoriasis, reducing inflammation and immune responses [(2)]. However, studies show that Bimzelx may be more effective at reducing body surface area (BSA) of psoriasis affected skin and improving quality of life compared to Taltz [(3)][(4)].

How do Bimzelx and Taltz compare in clinical trials?

A head-to-head study found that Bimzelx outperformed Taltz at 52 weeks, with 80% of patients achieving ≥75% reduction in BSA affected by psoriasis compared to 53% of Taltz-treated patients [(5)]. Another study published in the Journal of the American Academy of Dermatology reported significant improvements in skin clearance and quality of life with Bimzelx, although a small percentage of patients experienced side effects such as headaches and upper respiratory tract infections [(6)].

What are the differences in dosing regimens?

Unlike Taltz, which requires bi-weekly injections for the first week followed by bi-weekly injections for the remainder of the treatment period, Bimzelx can be administered as a once monthly injection [(7)][(8)]. This more simplified dosing regimen may be more convenient for patients and caregivers.

Are there any side effect differences between the two medications?

While both Bimzelx and Taltz can cause side effects, a review of clinical trials suggests that Bimzelx may have a lower incidence of adverse events, including anaphylaxis, Stevens-Johnson syndrome, and lupus-like reactions [(9)].

Patent Expiration and Market Impact

The Bimzelx patent is set to expire in 2032, which could lead to generic versions entering the market [(10)]. However, the manufacturer of Bimzelx has plans to file a patent extension [(11)], which may delay generic competition.

Sources:

1. DrugPatentWatch.com: Bimzelx (Bimekizumab) Patent Expiration
2. Bimzelx Mechanism of Action – AstraZeneca
3. Bimzelx Clinical Trials – AstraZeneca
4. Taltz Mechanism of Action – Eli Lilly
5. Bimzelx Head-to-Head Study vs. Taltz
6. Journal of the American Academy of Dermatology: Bimzelx Study
7. Bimzelx Dosing Regimen – AstraZeneca
8. Taltz Dosing Regimen – Eli Lilly
9. Clinical Review: Adverse Events in IL-17A Inhibitor Trials
10. DrugPatentWatch.com: Bimzelx Patent Expiration
11. AstraZeneca Plans to File Patent Extension for Bimzelx